We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I was hoping for a bit more of a rise this morning, on the back of this RNS.
Maybe it will be climb some more when America wakes up and starts trading?
Haleon could add this product to their many other and pay a large premium for the right. What nice patent they can own. Got to be worth close to £1.00 or more for them to take us out. Strong buy. Big upside potential.
Https://www.proactiveinvestors.co.uk/pdf/create_new/news/details/1028322
Yes granular detail on sales is important but it not the only thing that matters as we have new launches around the world, updates on Haleon’s plans for the US and a launch timetable for the world’s biggest market would be nice. The news this morning is terrific but just part of the overall puzzle which should put a floor on the share price if one follows logic but this is AIM. New traders will be buying this am no doubt along with some longer term holders seeing how cheap this is a 45p. A series of regular commercial updates would be good to allow some positive momentum to develop rather than this stop start pattern.
Sales figures are the only thing that matters from now on
Massively increases the value for the company
Dont under estimate the power of patents
Can be used on the packaging etc and its a massive marketing boost
Game changer for the co
Was the one missing link holding it back
Excellent news.futura have significant experience in patent applications, so im not surprised, but extremely good news to have this confirmed.
I would imagine a large chunk of marketing expenditure hinged on this news. We can start to make a louder noise now.
GLA.
BRILLIANT RNS... hopefully we will have a really good day here.
Yeah here too!
https://www.futuramedical.com/investor-centre/
I would suggest "buy"
Futura Medical PLC - European Patent Granted for MED3000 until 2040 #FUM https://www.voxmarkets.co.uk/rns/announcement/738b84d1-e596-4010-aacd-5b2db70562d6 #voxmarkets undefined
lots of issues, investors not happy it seems, i understand, but why on earth were these questions not put to the ceo & coo on the 19th sept instead of ******** on here? the floor was open to ask what we liked and jb and angela were there to answer!
I have posted here a lot more than had anticipated. So my story; Like all LTH,s the frustration is clear and understandable. I also bought in quite low and from the trial success on-wards have even ended averaging up. However, have kept this side of the waterline.
One thing to consider about the company is, that it is a totally different beast today. It is no longer an R&D only outfit and it has a valuable and proven product. (The PI,s 'patience clock' should have been reset form this moment)
I have been a critic of the BoD in the past and, like many others here, feel that there is much room for improvement, especially in the communications department.
The hub of frustration is that fundamentally, all the ducks remain lined up however, the SP is not showing respect. Two conclusions can be derived from this synopsis.
Something is wrong - time to sell up
It's far too early and the message is not getting through - stay invested.
Martinelwick - I agree, Coopers missed a trick with the messaging and branding (pricing(?)). I do feel that the US launch (and future launches) will have the learning curve applied.
- On Saturdays we are all football managers.
Just seen an advertisement for Cialis on tv.Makes the point it only works if “turned on”
I have commented before that there is a problem with managing expectations with Eroxon. I think many have the impression that it is some sort of aphrodisiac and then give a negative review when they don’t get a hard on.
Moreover it emerged that the longer you used Eroxon the better it worked.
Not only do we need a reset re presentation of our story but also the advertising message.
I should make it clear I am an investor in the true sense of the word having taken part in two placings,so I am beyond patience with the current situation.
ThanksTDH. it did indeed!
Italian
Fair summary.
Historically Viagra also evolved for ED via an route where its original tests were not for that!
Not really clear why you feel boarder and co were"clueless".pf course it was fortunate that the placebo results were as good as the trial drug(although that did of course mean that the drug failed its trial,so it cut both ways),but they then immediately seized the opportunity to go down the device route and successfully raised significant funds from LO (who have remained a firm supporter ever since ) to do so.the clueless board then successfully completed trails in both the EU and US.the requirements for a successful trial, even for a medical device, are highly exacting. im not suggesting that the current board is necessarily ideal to take things on to the next stage (i'm expecting a T/O at some point to enable LO to exit) but i do think some credit is due to it.and yes,im well aware of their less than glorious history before med3000.
I personally would like to see the product sold or company bought out as I have no faith in the Cheshire Cat (Barder) to make decisions at the right time. Let’s face it FUM were extremely Lucky with the product as even when faced with the trial results ,that without an active drug in Med3000 it was just as effective, they were clueless! Barder has been lucky! & that luck will run out eventually!
not sure merely pointing out meaning of the word 'investment' constitutes gas-lighting
...perhaps too much hicth**** peti!
Not sure one requires an economics 101 level knowledge to appreciate that we are dealing with a company who have absolutely no previous economic background to hang a hat on.
However, the known information is that the product works, has achieved accreditation and is selling well in a limited market. Two reputable marketers have signed distribution rights/deals.
Armed with this information one can decide whether to clutch at daily fluctuations of the SP or await further development and for it to start appearing in the City radar. One can argue that the later can be expiated by engaging with City friendly institutions.
However, I would lean towards trusting a CEO who has managed the company for 25 years, found, trialed and finally brought a product to fruition, managed to sign up two formidable international distributors, to drive it any which way he chooses, then go along with a few frustrated 'investors' wanting jam today!
Here here , could not agree more. We really have to dig deep to find the info we need ourselves and the information should be in Black and White through their presentations. I have been a LTH holder for a very long time as well with FUM and it is frustrating why the share price is not moving on the back of a series of good news. Seriously FUM themselves need to sell their story better to investors . I take nothing away from the hard work they have done in the last few years with regards to the milestones they have achieved which is to be applauded but please invest in some Investor relations/PR person to sell the story better , I also like the suggestion of having a share price target as a KPI
Gaslighting - denying another person’s reality - is rife in all walks of life. So no surprise it’s present on this board.
Quite a few of us are miffed that - after James Barder gives 3 presentations of essentially the same material, skates over sales volumes, fails to link these volumes to countries and retailer numbers, and provides a super-cautious outlook - the share price slips back over 20%.
Some scribes on here tell us that we are short-termists, and should instead sit back and be quiet, because value will eventually out.
As anyone with Economics 101-level knowledge is aware, markets can fail, so that market prices are no longer ‘efficient’ or even ‘rational’ - perhaps for many years. Hence Keynes’ argument that governments need to intervene in markets with spending, or the presence of regulators to control monopolistic practices….
Far less is known about Futura than, say, Rio Tinto or Tesco. There’s less and poorer quality analyst coverage. With fewer followers, including investors, there’s a much higher probability that Futura’s share price will be inefficient, and can be manipulated through bulletin boards, for example. Just look at the pathetically small volumes that sometimes determine its uncrossing price, and so whether it is up or down on the day.
I first invested in Futura at 8p in early 2020, drawn by the “statistically significant and clinically meaningful top line results” of its placebo used in the MED2005 Phase 3 study. So, a 5x return to date. Therefore, I’m not a short term trader, nor am I an ‘under the water’ investor.
To the gaslighters: my concern is not with Futura’s price since last week, since last month, or even since last year. It is that it has gone nowhere since spring 2021, or for 2-3 years, despite the growing list of important operational objectives achieved by the company. Even James Barder has expressed surprise about this in his interviews.
Can more be done to address this poor share price performance? Of course! The comms is dire. Too many ‘retreads’ of information in RNSs, in interviews / investor meets, too much background information about the company, rather than value-adding information about volumes, revenues, shareholder returns…Why isn’t James Barder on some of these TV / news programmes to tell the world about Eroxon? Why are we not changing to a company broker with more powerful fund management clients, rather than the ‘cheap and cheerful’ ones we have at present that the investment community is simply ignoring?
Futura’s Executive needs to include the share price level as an important strategic objective, and be managing levers within their control to achieve and maintain that level. Personally, I want to see Futura’s share always be on the outside of the envelope of its possible value, not languishing as in the past few years (according to those brokers) way inside, at a fraction of its value.
Seems to reinforce the resistance around 42p. A flurry of fairly large buys going through.